Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXSM NASDAQ:CRSP NASDAQ:EWTX NASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$125.17+0.6%$110.23$75.56▼$139.13$6.21B0.54510,939 shs506,617 shsCRSPCRISPR Therapeutics$54.86+4.0%$56.36$30.04▼$71.13$4.99B1.812.18 million shs2.73 million shsEWTXEdgewise Therapeutics$15.57+6.5%$13.88$10.60▼$38.12$1.54B0.26760,660 shs847,053 shsTLXTelix Pharmaceuticals$9.06-0.2%$13.22$8.93▼$30.36$3.07BN/A230,216 shs123,617 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics+0.61%+3.21%+21.22%+11.85%+30.99%CRSPCRISPR Therapeutics+4.02%+5.85%-2.63%+31.06%+21.83%EWTXEdgewise Therapeutics+6.50%+8.50%+15.16%+2.17%-13.16%TLXTelix Pharmaceuticals-0.22%-5.13%-24.31%-45.97%+905,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$125.17+0.6%$110.23$75.56▼$139.13$6.21B0.54510,939 shs506,617 shsCRSPCRISPR Therapeutics$54.86+4.0%$56.36$30.04▼$71.13$4.99B1.812.18 million shs2.73 million shsEWTXEdgewise Therapeutics$15.57+6.5%$13.88$10.60▼$38.12$1.54B0.26760,660 shs847,053 shsTLXTelix Pharmaceuticals$9.06-0.2%$13.22$8.93▼$30.36$3.07BN/A230,216 shs123,617 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics+0.61%+3.21%+21.22%+11.85%+30.99%CRSPCRISPR Therapeutics+4.02%+5.85%-2.63%+31.06%+21.83%EWTXEdgewise Therapeutics+6.50%+8.50%+15.16%+2.17%-13.16%TLXTelix Pharmaceuticals-0.22%-5.13%-24.31%-45.97%+905,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXSMAxsome Therapeutics 3.13Buy$177.8642.09% UpsideCRSPCRISPR Therapeutics 2.47Hold$71.6030.51% UpsideEWTXEdgewise Therapeutics 2.91Moderate Buy$40.55160.41% UpsideTLXTelix Pharmaceuticals 2.80Moderate Buy$22.33146.50% UpsideCurrent Analyst Ratings BreakdownLatest EWTX, TLX, AXSM, and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025AXSMAxsome TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/2/2025AXSMAxsome TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$163.008/28/2025TLXTelix PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral8/28/2025TLXTelix PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$22.008/26/2025CRSPCRISPR TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/19/2025EWTXEdgewise TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$40.00 ➝ $30.008/8/2025EWTXEdgewise TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$48.00 ➝ $49.008/7/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$65.00 ➝ $80.008/6/2025CRSPCRISPR TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$42.00 ➝ $56.008/5/2025AXSMAxsome TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$173.00 ➝ $176.008/5/2025AXSMAxsome TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$184.00 ➝ $189.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXSMAxsome Therapeutics$385.69M16.19N/AN/A$1.18 per share106.08CRSPCRISPR Therapeutics$35M142.56N/AN/A$22.64 per share2.42EWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.84 per shareN/ATLXTelix Pharmaceuticals$516.72M5.93$0.11 per share79.51$1.12 per share8.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXSMAxsome Therapeutics-$287.22M-$5.07N/A44.39N/A-49.88%-283.22%-33.06%11/11/2025 (Estimated)CRSPCRISPR Therapeutics-$366.25M-$5.43N/AN/AN/A-1,229.43%-20.05%-17.09%11/4/2025 (Estimated)EWTXEdgewise Therapeutics-$133.81M-$1.55N/AN/AN/AN/A-30.65%-29.18%11/6/2025 (Estimated)TLXTelix Pharmaceuticals$32.93MN/A0.0018.88N/AN/AN/AN/AN/ALatest EWTX, TLX, AXSM, and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025EWTXEdgewise Therapeutics-$0.42-$0.34+$0.08-$0.34N/AN/A8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 million8/4/2025Q2 2025CRSPCRISPR Therapeutics-$1.47-$1.29+$0.18-$2.40$6.44 million$0.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXSMAxsome Therapeutics1.661.571.51CRSPCRISPR TherapeuticsN/A16.6116.61EWTXEdgewise TherapeuticsN/A28.8728.87TLXTelix Pharmaceuticals0.992.782.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXSMAxsome Therapeutics81.49%CRSPCRISPR Therapeutics69.20%EWTXEdgewise TherapeuticsN/ATLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAXSMAxsome Therapeutics22.30%CRSPCRISPR Therapeutics4.30%EWTXEdgewise Therapeutics23.20%TLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXSMAxsome Therapeutics38049.90 million38.77 millionOptionableCRSPCRISPR Therapeutics46090.95 million87.04 millionOptionableEWTXEdgewise Therapeutics60105.35 million80.91 millionOptionableTLXTelix PharmaceuticalsN/A338.40 millionN/AN/AEWTX, TLX, AXSM, and CRSP HeadlinesRecent News About These CompaniesRosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLXSeptember 5 at 8:33 PM | prnewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Sets New 12-Month Low - What's Next?September 5 at 5:18 AM | marketbeat.comTelix Pharmaceuticals (ASX:TLX) Hits New Low Amid FDA ScrutinySeptember 5 at 5:15 AM | thebull.com.auTTelix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - What's Next?September 4 at 1:23 PM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLXSeptember 3 at 10:00 AM | prnewswire.comTelix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response LetterSeptember 2, 2025 | finance.yahoo.comFY2026 Earnings Forecast for TLX Issued By William BlairSeptember 2, 2025 | marketbeat.comResearch Analysts Set Expectations for TLX FY2026 EarningsSeptember 2, 2025 | americanbankingnews.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's WhyAugust 31, 2025 | marketbeat.comWilliam Blair Has Bearish Estimate for TLX FY2027 EarningsAugust 31, 2025 | marketbeat.comWedbush Analysts Decrease Earnings Estimates for TLXAugust 31, 2025 | marketbeat.comWilliam Blair Has Pessimistic View of TLX FY2027 EarningsAugust 31, 2025 | americanbankingnews.comFY2025 EPS Estimate for Telix Pharmaceuticals Cut by AnalystAugust 31, 2025 | americanbankingnews.comTelix Pharmaceuticals (NASDAQ:TLX) Reaches New 12-Month Low - Here's What HappenedAugust 30, 2025 | marketbeat.comTelix Pharmaceuticals (NASDAQ:TLX) Earns "Outperform" Rating from WedbushAugust 30, 2025 | marketbeat.comWedbush Reiterates "Outperform" Rating for Telix Pharmaceuticals (NASDAQ:TLX)August 30, 2025 | americanbankingnews.comTelix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again -- Hagens BermanAugust 29, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLXAugust 29, 2025 | globenewswire.comHealth Check: Angry investors birch Telix shares after third US regulatory setbackAugust 29, 2025 | msn.comTelix Pharmaceuticals' (TLX) "Neutral" Rating Reaffirmed at JPMorgan Chase & Co.August 29, 2025 | americanbankingnews.comAustralia's Telix Pharma says FDA seeks more data on cancer diagnostic drug; shares plungeAugust 28, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEWTX, TLX, AXSM, and CRSP Company DescriptionsAxsome Therapeutics NASDAQ:AXSM$125.17 +0.76 (+0.61%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$126.23 +1.06 (+0.85%) As of 09/5/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.CRISPR Therapeutics NASDAQ:CRSP$54.86 +2.12 (+4.02%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$54.62 -0.23 (-0.43%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Edgewise Therapeutics NASDAQ:EWTX$15.57 +0.95 (+6.50%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$15.64 +0.07 (+0.48%) As of 09/5/2025 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Telix Pharmaceuticals NASDAQ:TLX$9.06 -0.02 (-0.22%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$9.20 +0.15 (+1.60%) As of 09/5/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
